(Q44487146)

English

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study (English)

1 reference

Europe PubMed Central

3 December 2017

1 reference

based on heuristic

inferred from title

author name string

Margarita A Morozova

1

1 reference

Europe PubMed Central

3 December 2017

Taisiya A Lepilkina

2

1 reference

Europe PubMed Central

3 December 2017

Georgy E Rupchev

3

1 reference

Europe PubMed Central

3 December 2017

Allan G Beniashvily

4

1 reference

Europe PubMed Central

3 December 2017

Denis S Burminskiy

5

1 reference

Europe PubMed Central

3 December 2017

Sergey S Potanin

6

1 reference

Europe PubMed Central

3 December 2017

Evgeny V Bondarenko

7

1 reference

Europe PubMed Central

3 December 2017

Vasily I Kazey

8

1 reference

Europe PubMed Central

3 December 2017

Yan Lavrovsky

9

1 reference

Europe PubMed Central

3 December 2017

Alexandre V Ivachtchenko

10

1 reference

Europe PubMed Central

3 December 2017

publication date

17 June 2013

1 reference

Europe PubMed Central

3 December 2017

C N S Spectrums

1 reference

Europe PubMed Central

3 December 2017

19

1 reference

Europe PubMed Central

3 December 2017

4

1 reference

Europe PubMed Central

3 December 2017

316-323

1 reference

Europe PubMed Central

3 December 2017

The serotonin-6 receptor as a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

5-HT6 receptor antagonists as potential therapeutics for cognitive impairment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Drug-responsive symptoms during early neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Role of the cholinesterase inhibitors in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Alterations of serotonin transmission in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Muscarinic mechanisms in psychotic disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

The glutamate hypothesis of schizophrenia: neuroimaging and drug development

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Research on attention networks as a model for the integration of psychological science

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Psychosocial functioning and cognitive deficits are not associated with membrane-bound catechol-O-methyltransferase deoxyribonucleic acid methylation in siblings of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Beneficial effects of add-on raloxifene in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Adjunct mirtazapine for negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Validation of the 16-item Negative Symptom Assessment.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Neurocognitive impairment in schizophrenia and how it affects treatment options

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Cognitive function in schizophrenia--do neuroleptics make a difference?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

21 January 2018

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

7 January 2021

based on heuristic

inferred from DOI database lookup

Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

7 January 2021

based on heuristic

inferred from DOI database lookup

A depression rating scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

7 January 2021

based on heuristic

inferred from DOI database lookup

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000394

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1092852913000394

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44487146&oldid=2025564514"